Challenging widespread clinical practice and accepted treatment guidelines, Dr. Holly Prigerson has published a paper in JAMA Oncology that puts the value of chemotherapy for end-of-life patients with cancer into question. Among several findings, it was found that patients who were ambulatory (able to do light work) and receiving chemotherapy at study entry, had significantly lower quality of life at the end of their lives compared to those who were not receiving chemotherapy.
The Mayo Clinic has received an $11 million grant from the National Cancer Institute to support research addressing current and long-term unmet healthcare needs of people with non-Hodgkin lymphoma (NHL). The is a collaborative effort among multiple institutions.
This award is presented annually to members of the Weill Department of Medicine below the rank of professor who perform on outstanding levels in the areas of clinical and/or basic biomedical research. It is supported by the Michael Wolk Foundation.
Initiated in 2002, the Fellow Award in Research is presented annually to fellows within the Weill Department of Medicine who have presented outstanding research. This year's finalists were announced at the June 10 Medicine Grand Rounds (13th Annual).
Dr. Faltas is currently focused on molecular profiling of metastatic platinum-resistant urothelial bladder carcinoma, a disease with no approved therapies. In particular, he is investigating the molecular changes that occur as urothelial cancer evolves under the effect of chemotherapy and metastatic spread. Identifying these molecular changes will hopefully lead to finding "druggable" targets for translation into therapeutic clinical trials.
The new findings that innate lymphoid cells (ILCs) directly educate T cells in the intestine to not attack beneficial bacteria, and that impairment of ILC function leads to severe intestinal inflammation. Critically, they also demonstrate that loss of MHCII (a type of machinery that delivers signals to T cells) on ILCs is linked to pro-inflammatory cells in patients with IBD (Inflammatory Bowel Disease).
The award, which recognizes major contributions to the advancement of scientific knowledge, was presented to Dr. Patterson at the College's 64th Annual Scientific Session. Dr. Patterson, a Professor of Medicine in the Weill Department of Medicine (WDOM), is the newly recruited Senior Vice President & Chief Operating Officer at NewYork-Presbyterian/Weill Cornell Medical Center.
Membership to the AAP is a coveted honor and reflects remarkable dedication to the advancement of scientific and practical medicine. Founded in 1885 as a non-profit professional organization, the AAP has some 1,300 active members and 600 honorary members.
The Weill Department of Medicine is focused on increasing its research footprint both at Weill Cornell and on a national level. To that end, the department has established a mentoring infrastructure to assist junior faculty during their transition to NIH K and R series grants. This infrastructure supports a monthly meeting that seeks to build, promote, and mentor the department's junior faculty.
Founded in 1908, the American Society of Clinical Investigation is an honor society of some 3,000 physician-scientists who serve in the upper ranks of academic medicine and industry. Those who become members of ASCI are premier leaders in translating findings from the laboratory to the advancement of clinical practice.
